Abstract
Angiogenesis is central to cancer research. Recent progresses in understanding its mechanisms have enabled the development of therapies that inhibit this process. Many molecules have shown a synergistic effect in combination with irradiation in preclinical studies, and several are being tested in phase I or II. This effect could be explained by a transient normalization of tumor vasculature, leading to improve tumor oxygenation and thus greater radiosensitivity. Although promising, many questions remain about the dose, optimal sequences of the association.
MeSH terms
-
Angiogenesis Inhibitors / therapeutic use*
-
Clinical Trials as Topic
-
Combined Modality Therapy
-
Fibroblast Growth Factor 2 / antagonists & inhibitors
-
Humans
-
Neoplasms / blood supply*
-
Neoplasms / radiotherapy*
-
Neoplastic Stem Cells / drug effects
-
Neoplastic Stem Cells / physiology
-
Neoplastic Stem Cells / radiation effects
-
Radiation Tolerance / drug effects
-
Radiation Tolerance / physiology
-
Radiotherapy / methods*
-
Vascular Endothelial Growth Factor A / antagonists & inhibitors
Substances
-
Angiogenesis Inhibitors
-
Vascular Endothelial Growth Factor A
-
Fibroblast Growth Factor 2